StockData
Integra LifeSciences Holdings Corp logo

Integra LifeSciences Holdings Corp (IART) stock

IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 9/308% below fair value
$13.86+0.31 (+2.29%)

Close on Nov 18, 2026Market cap $1.08BP/E 81.5Yield –

Integra LifeSciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Integra LifeSciences's operating income for the twelve months ending Sep 30, 2026 was $72.70M. For fiscal 2025 it was -$493.37M, down 1836.5% from the year before. The highest annual figure on record is $238.92M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$493.37M-1836.5%
FY2024Dec 31, 2024$28.41M-74.5%
FY2023Dec 31, 2023$111.53M-53.3%
FY2022Dec 31, 2022$238.92M+21.1%
FY2021Dec 31, 2021$197.23M+30.3%
FY2020Dec 31, 2020$151.37M+61.4%
FY2019Dec 31, 2019$93.76M-15.5%
FY2018Dec 31, 2018$111.00M+147.7%
FY2017Dec 31, 2017$44.80M-61.2%
FY2016Dec 31, 2016$115.34M+44.9%
FY2015Dec 31, 2015$79.59M+17.3%
FY2014Dec 31, 2014$67.86M+91.8%
FY2013Dec 31, 2013$35.37M-52.1%
FY2012Dec 31, 2012$73.78M+34.4%
FY2011Dec 31, 2011$54.91M-44.4%
FY2010Dec 31, 2010$98.69M+0.9%
FY2009Dec 31, 2009$97.82M+106.3%
FY2008Dec 31, 2008$47.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$18.90M+60.7%
Q2 FY2026Jun 30, 2026$19.29M–
Q1 FY2026Mar 31, 2026$11.47M–
Q4 FY2025Dec 31, 2025$23.04M-35.3%
Q3 FY2025Sep 30, 2025$11.76M–
Q2 FY2025Jun 30, 2025-$512.67M–
Q1 FY2025Mar 31, 2025-$15.50M-490.9%
Q4 FY2024Dec 31, 2024$35.63M-1.2%
Q3 FY2024Sep 30, 2024-$8.15M-130.6%
Q2 FY2024Jun 30, 2024-$3.03M-124.2%
Q1 FY2024Mar 31, 2024$3.96M-89.1%
Q4 FY2023Dec 31, 2023$36.05M-46.9%
Q3 FY2023Sep 30, 2023$26.59M-59.1%
Q2 FY2023Jun 30, 2023$12.50M-79.1%
Q1 FY2023Mar 31, 2023$36.38M-21.2%
Q4 FY2022Dec 31, 2022$67.84M+16.5%
Q3 FY2022Sep 30, 2022$65.05M+15.3%
Q2 FY2022Jun 30, 2022$59.87M+15.5%
Q1 FY2022Mar 31, 2022$46.16M+50.3%
Q4 FY2021Dec 31, 2021$58.22M+10.6%
Q3 FY2021Sep 30, 2021$56.44M-1.9%
Q2 FY2021Jun 30, 2021$51.85M+268.3%
Q1 FY2021Mar 31, 2021$30.71M+13.3%
Q4 FY2020Dec 31, 2020$52.65M+45.9%
Q3 FY2020Sep 30, 2020$57.54M–
Q2 FY2020Jun 30, 2020$14.08M-69.4%
Q1 FY2020Mar 31, 2020$27.10M-16.1%
Q4 FY2019Dec 31, 2019$36.08M+5.8%
Q3 FY2019Sep 30, 2019-$20.59M-186.9%
Q2 FY2019Jun 30, 2019$45.96M+66.3%
Q1 FY2019Mar 31, 2019$32.31M+26.3%
Q4 FY2018Dec 31, 2018$34.11M+372.5%
Q3 FY2018Sep 30, 2018$23.68M+122.5%
Q2 FY2018Jun 30, 2018$27.63M+62.7%
Q1 FY2018Mar 31, 2018$25.58M+156.8%
Q4 FY2017Dec 31, 2017$7.22M-82.3%
Q3 FY2017Sep 30, 2017$10.64M–
Q2 FY2017Jun 30, 2017$16.99M–
Q1 FY2017Mar 31, 2017$9.96M–
Q4 FY2016Dec 31, 2016$40.77M–

More Integra LifeSciences figures

See a number that looks wrong?